Kymera Therapeutics
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $2,764 | $11,476 | $22,100 | $7,394 |
Gross Profit | -71,330 | 9,392 | 22,100 | 7,394 |
EBITDA | -79,326 | -74,422 | -63,461 | -68,706 |
EBIT | -82,175 | -76,506 | -65,509 | -70,693 |
Net Income | -82,175 | -76,614 | -65,581 | -70,752 |
Net Change In Cash | 2,764 | 11,476 | 22,100 | 7,394 |
Free Cash Flow | -27,291 | -60,579 | -79,617 | -62,720 |
Cash | 112,949 | 335,816 | 89,966 | 120,256 |
Basic Shares | 87,300 | 80,449 | 80,146 | 79,987 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $47,072 | $78,592 | $46,826 | $72,832 |
Gross Profit | 47,072 | 78,592 | 46,826 | 72,832 |
EBITDA | -216,236 | -143,201 | -151,655 | -97,645 |
EBIT | -223,609 | -146,766 | -154,632 | -100,042 |
Net Income | -223,858 | -146,962 | -154,808 | -100,217 |
Net Change In Cash | 47,072 | 78,592 | 46,826 | 72,832 |
Cost of Revenue | 20,433 | 21,499 | ||
Free Cash Flow | -207,339 | -137,305 | -155,921 | -130,543 |
Cash | 120,256 | 109,966 | 68,395 | 47,976 |
Basic Shares | 75,043 | 58,365 | 53,933 | 47,989 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | -$0.94 |
2025-06-30 | -$0.95 |
2025-03-31 | -$0.82 |
2024-12-31 | -$0.89 |
